Raymond James Reinstates Outperform on Sarepta Therapeutics, Announces $150 Price Target
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has reinstated an Outperform rating on Sarepta Therapeutics (NASDAQ:SRPT) and set a price target of $150.
October 10, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has reinstated an Outperform rating on Sarepta Therapeutics with a price target of $150, indicating a positive outlook for the stock.
The reinstatement of an Outperform rating and a $150 price target by Raymond James suggests a positive short-term outlook for Sarepta Therapeutics. This could lead to increased investor confidence and potential stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100